Who Can Take Ozempic: The FDA Criteria, Absolute Contraindications, and the Clinical Decision Framework Providers Actually Use

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) is FDA-approved for adults with type 2 diabetes and BMI ≥27 with weight-related comorbidities, not for type 1 diabetes or weight loss alone (that's Wegovy's indication)
• Absolute contraindications include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and documented severe allergic reaction to semaglutide
• Relative exclusions (requiring provider judgment) include active pancreatitis, severe gastroparesis, pregnancy or breastfeeding, diabetic retinopathy requiring active treatment, and age under 18
• The clinical decision framework weighs three factors: FDA label indication, contraindication screening, and individual risk-benefit analysis based on comorbidities and treatment history

Direct answer (40-60 words)

Ozempic is FDA-approved for adults with type 2 diabetes to improve glycemic control, typically when metformin alone is insufficient. Candidates must not have personal or family history of medullary thyroid cancer, MEN2 syndrome, or prior severe reaction to GLP-1 medications. The medication is not approved for type 1 diabetes, weight loss as sole indication, or patients under 18.

Table of contents

1. The FDA-approved indication: what Ozempic is actually approved for
2. Absolute contraindications: who cannot take Ozempic under any circumstance
3. Relative contraindications: conditions requiring provider judgment
4. The BMI and comorbidity question: when weight matters for eligibility
5. Age restrictions and pediatric use
6. What most articles get wrong about off-label use
7. The clinical decision framework: how providers actually determine eligibility
8. Ozempic vs Wegovy vs compounded semaglutide: eligibility differences
9. Pre-existing conditions that change the risk-benefit calculation
10. The screening checklist providers use before prescribing
11. When you need specialist clearance before starting
12. FAQ

The FDA-approved indication: what Ozempic is actually approved for

Ozempic received FDA approval in December 2017 for a single indication: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. That's it. The label does not include type 1 diabetes, prediabetes, metabolic syndrome, or weight loss as a standalone goal.

The approval was based on the SUSTAIN clinical trial program (SUSTAIN-1 through SUSTAIN-10), which enrolled over 8,000 patients with type 2 diabetes. The primary endpoints were HbA1c reduction and, in cardiovascular outcomes trials like SUSTAIN-6, major adverse cardiovascular events (Marso et al., New England Journal of Medicine 2016).

Weight loss was a secondary endpoint in these trials. Patients lost an average of 4.5 kg (9.9 lbs) on the 0.5 mg dose and 6.5 kg (14.3 lbs) on the 1 mg dose over 30 weeks (Sorli et al., Diabetes Care 2017). The FDA noted this benefit but did not approve Ozempic for weight management. That indication went to Wegovy (same molecule, higher dose, different approval pathway) in June 2021.

This distinction matters because insurance coverage, prescribing guidelines, and legal liability all hinge on FDA-approved indications. A provider can prescribe Ozempic off-label for weight loss (off-label prescribing is legal and common), but the patient and provider assume different coverage and liability positions than with on-label use.

The core eligibility question starts here: do you have type 2 diabetes diagnosed by standard criteria (fasting glucose ≥126 mg/dL, HbA1c ≥6.5%, or 2-hour glucose ≥200 mg/dL during oral glucose tolerance test)? If yes, you meet the foundational FDA indication. If no, any Ozempic prescription is off-label.

Absolute contraindications: who cannot take Ozempic under any circumstance

The FDA label lists three absolute contraindications. These are not "use with caution" situations. These are "do not prescribe under any circumstance."

1. Personal or family history of medullary thyroid carcinoma (MTC).

Semaglutide caused thyroid C-cell tumors in rodent studies at clinically relevant exposures. The mechanism involves GLP-1 receptor activation on thyroid C-cells, which proliferate in response. Humans have far fewer thyroid C-cell GLP-1 receptors than rodents, but the signal was strong enough that the FDA required a black-box warning.

MTC represents less than 4% of thyroid cancers but is aggressive and often hereditary. If you or a first-degree relative (parent, sibling, child) has had MTC, semaglutide is contraindicated. Period. No dose is considered safe (Hegedüs et al., Endocrine Reviews 2023).

2. Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

MEN2 is a hereditary syndrome causing MTC, pheochromocytoma, and parathyroid tumors. It's caused by RET proto-oncogene mutations. Patients with known MEN2 or genetic carriers are absolutely excluded from GLP-1 receptor agonist therapy. The MTC risk in MEN2 patients exposed to GLP-1 agonists is considered unacceptably high based on the rodent data and the known biology of RET-driven tumors.

3. Prior serious hypersensitivity reaction to semaglutide or any excipient.

Anaphylaxis to semaglutide is rare but documented. If a patient has had anaphylaxis, angioedema, or severe urticaria in response to any semaglutide-containing product (Ozempic, Wegovy, Rybelsus), rechallenge is contraindicated. Cross-reactivity with other GLP-1 agonists (liraglutide, tirzepatide) is possible but not guaranteed; switching to a different GLP-1 class member requires allergist consultation.

These three contraindications are screening questions every provider asks before the first prescription. If any answer is yes, the conversation ends there.

Relative contraindications: conditions requiring provider judgment

Relative contraindications are conditions where Ozempic is not automatically excluded but where the risk-benefit balance shifts enough to require careful evaluation and often specialist input.

Active or recent pancreatitis.

GLP-1 receptor agonists are associated with a small but real increase in acute pancreatitis risk. A 2022 meta-analysis (Azoulay et al., JAMA Internal Medicine) found a hazard ratio of 1.4 (95% CI 1.1-1.8) compared to other diabetes medications. The absolute risk is low (about 4 cases per 1,000 patient-years), but patients with prior pancreatitis have higher baseline risk.

Most providers avoid semaglutide in patients with pancreatitis within the past 6 months. For remote history (more than 2 years), the decision depends on whether the cause was identified and resolved (gallstones removed, alcohol cessation) or idiopathic. Idiopathic recurrent pancreatitis is a stronger relative contraindication.

Severe gastroparesis.

Semaglutide slows gastric emptying, which is therapeutic for diabetes and satiety but problematic in patients with pre-existing severe gastroparesis. The concern is worsening nausea, vomiting, and nutritional compromise. Mild gastroparesis (delayed emptying on gastric emptying study but minimal symptoms) is not an automatic exclusion, but severe symptomatic gastroparesis usually is.

Pregnancy and breastfeeding.

Semaglutide is Pregnancy Category C (animal studies showed fetal harm, no adequate human studies). The FDA label recommends discontinuing Ozempic at least 2 months before planned pregnancy due to the drug's long half-life (approximately 1 week). Unplanned pregnancy during treatment warrants immediate discontinuation.

Breastfeeding data are limited. Semaglutide is a large peptide (molecular weight 4,113 Da) unlikely to pass into breast milk in significant quantities, but no studies confirm safety. Most providers recommend against use during breastfeeding.

Diabetic retinopathy requiring active treatment.

The SUSTAIN-6 cardiovascular outcomes trial found a surprising signal: more diabetic retinopathy complications in the semaglutide group (3.0%) vs placebo (1.8%), hazard ratio 1.76 (Marso et al., NEJM 2016). The mechanism appears related to rapid HbA1c reduction in patients with pre-existing retinopathy, causing temporary worsening (a known phenomenon with any rapid glycemic improvement).

Patients with proliferative diabetic retinopathy or macular edema requiring active laser or anti-VEGF treatment are typically excluded or require ophthalmology clearance before starting semaglutide. Patients with mild background retinopathy can usually proceed with close ophthalmologic monitoring.

Severe renal impairment (eGFR <15 mL/min/1.73 m² or dialysis).

Semaglutide is not renally cleared, so dose adjustment is not required for renal impairment. However, patients with severe kidney disease have higher rates of nausea and dehydration on GLP-1 agonists, and volume depletion can worsen renal function. The drug is not contraindicated in end-stage renal disease, but use requires careful volume status monitoring.

History of suicidal ideation or severe depression.

This is a newly emerging concern. The FDA is investigating reports of suicidal ideation in patients on GLP-1 receptor agonists, though causality is not established (FDA Drug Safety Communication, 2024). Patients with active suicidal ideation or recent psychiatric hospitalization are often excluded pending further data. Stable depression on treatment is not an automatic exclusion.

The BMI and comorbidity question: when weight matters for eligibility

For on-label Ozempic use (type 2 diabetes), there is no BMI requirement. A patient with type 2 diabetes and BMI of 22 qualifies just as much as one with BMI of 40. The FDA approval was for glycemic control, not weight.

For off-label weight-loss use, providers typically follow the Wegovy eligibility criteria as a guideline:

• BMI ≥30, or
• BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)

This is not an FDA requirement for Ozempic but a clinical standard borrowed from the weight-management indication. Insurance prior authorization for off-label Ozempic weight-loss use almost always requires meeting these BMI thresholds.

The comorbidity list matters. A patient with BMI 28 and hypertension qualifies under the ≥27 + comorbidity pathway. A patient with BMI 28 and no comorbidities does not, at least not for insurance coverage. Out-of-pocket prescriptions follow provider discretion.

One pattern we see consistently in FormBlends consultations: patients with BMI 25-27 and prediabetes (HbA1c 5.7-6.4%) seeking Ozempic for diabetes prevention. This is off-label and not supported by FDA-approved indications, but it's a growing use case. The Diabetes Prevention Program trial showed lifestyle intervention reduces diabetes incidence by 58% in this population (Knowler et al., NEJM 2002), and some providers view GLP-1 agonists as pharmacologic augmentation of that approach. Coverage is nearly impossible; this is a cash-pay scenario.

Age restrictions and pediatric use

Ozempic is approved for adults 18 and older. It is not approved for pediatric use in any indication.

Wegovy received FDA approval for adolescents ages 12 and up with obesity (BMI ≥95th percentile for age and sex) in December 2022, based on the STEP TEENS trial (Weghuber et al., NEJM 2022). This creates a confusing landscape: the same molecule (semaglutide) is approved for adolescents at 2.4 mg weekly (Wegovy) but not at 0.5-1 mg weekly (Ozempic).

In practice, pediatric endocrinologists sometimes prescribe Ozempic off-label for adolescents with type 2 diabetes, particularly when Wegovy is unavailable or unaffordable. This is legally permissible but requires careful informed consent and typically institutional ethics committee review.

For adults over 65, there is no upper age limit. The SUSTAIN trials included patients up to age 88. Older adults have higher rates of nausea and dehydration, so slower titration is common, but age alone is not a contraindication.

What most articles get wrong about off-label use

Most patient-facing articles conflate "FDA-approved" with "legal to prescribe" and "covered by insurance." These are three separate questions.

The error: "Ozempic is only for people with diabetes, so if you don't have diabetes, you can't get it."

The correction: Ozempic is FDA-approved only for type 2 diabetes, but off-label prescribing is legal, common, and ethically appropriate when the provider judges the benefit-risk ratio favorable. The American Medical Association and FDA both affirm that off-label prescribing is a core component of medical practice (Radley et al., Archives of Internal Medicine 2006).

An estimated 40% of Ozempic prescriptions written in 2023 were for off-label weight loss, not diabetes (IQVIA prescription data). This is not illegal. It's not unethical. It's standard practice.

The constraint is insurance coverage. Payers almost never cover off-label Ozempic for weight loss. They will cover Wegovy (if the patient meets BMI criteria and the drug is available), but Ozempic off-label is typically denied. The patient can still get the prescription and pay out of pocket, or use compounded semaglutide, which is not FDA-approved but is legal when prescribed individually.

The second error: "You need to try metformin first before you can get Ozempic."

This is a payer requirement, not an FDA requirement. The FDA label says Ozempic is "indicated as an adjunct to diet and exercise," not "as an adjunct after metformin failure." Many insurance plans require step therapy (metformin, then sulfonylurea, then GLP-1 agonist), but this is a coverage policy, not a medical necessity. A provider can prescribe Ozempic as first-line therapy if clinically appropriate. The patient may just have to pay cash.

The clinical decision framework: how providers actually determine eligibility

The eligibility question in real clinical practice follows a three-layer framework.

Layer 1: Does the patient meet an FDA-approved indication?

• Type 2 diabetes? Yes → proceed to Layer 2.
• No diabetes but BMI ≥27-30 and seeking weight loss? This is off-label for Ozempic but on-label for Wegovy. If Wegovy is available and covered, prescribe that. If not, Ozempic off-label or compounded semaglutide are options.

Layer 2: Screen for absolute contraindications.

• Personal or family history of MTC? Yes → stop, do not prescribe.
• MEN2 or RET mutation? Yes → stop.
• Prior anaphylaxis to semaglutide? Yes → stop.
• If all three are no → proceed to Layer 3.

Layer 3: Evaluate relative contraindications and individual risk factors.

This is where clinical judgment lives. The provider weighs:

• Severity of diabetes or obesity vs risk of side effects
• Presence of comorbidities that semaglutide might improve (cardiovascular disease, fatty liver, sleep apnea)
• Presence of conditions that increase risk (active retinopathy, recent pancreatitis, gastroparesis)
• Patient's prior medication trials and tolerance
• Patient's ability to adhere to injection schedule and monitoring

A 55-year-old with type 2 diabetes, HbA1c 9.2%, BMI 38, hypertension, and prior metformin failure is a strong candidate. The cardiovascular benefit (SUSTAIN-6 showed 26% reduction in major adverse cardiovascular events) and weight loss outweigh the modest pancreatitis and nausea risk.

A 30-year-old with BMI 28, no comorbidities, no diabetes, seeking cosmetic weight loss is a weak candidate for Ozempic. The risk-benefit ratio doesn't favor a lifelong injectable medication with black-box warnings when lifestyle intervention hasn't been attempted.

The framework is not algorithmic. Two providers can reasonably disagree on the same patient. This is why "who can take Ozempic" doesn't have a simple checklist answer.

[Diagram suggestion: Three-layer funnel diagram. Top layer: "FDA Indication?" (Type 2 diabetes yes/no, BMI criteria). Middle layer: "Absolute Contraindications?" (MTC, MEN2, anaphylaxis). Bottom layer: "Risk-Benefit Analysis" (comorbidities, prior treatments, individual factors). Arrow flows top to bottom, with "Stop" exits at each layer if criteria not met.]

Ozempic vs Wegovy vs compounded semaglutide: eligibility differences

All three contain semaglutide, but eligibility and coverage differ.

Product	FDA indication	Typical dose	Eligibility	Coverage
Ozempic	Type 2 diabetes	0.5 mg or 1 mg weekly	Adults with T2D	Covered by most insurance for diabetes
Wegovy	Chronic weight management	2.4 mg weekly	BMI ≥30 or ≥27 + comorbidity, age ≥12	Covered by some insurance; many exclude weight-loss drugs
Compounded semaglutide	None (not FDA-approved)	0.25-2.5 mg weekly (variable)	Provider discretion	Not covered; cash pay only

Compounded semaglutide occupies a unique space. It is not FDA-approved, so there is no official eligibility criterion. Prescribing is at provider discretion under state pharmacy compounding laws. Most compounding pharmacies follow the Wegovy BMI criteria as a guideline, but this is not legally required.

The practical eligibility difference: if you have type 2 diabetes and insurance, Ozempic is the first choice (covered). If you have obesity without diabetes and insurance covers weight-loss medications, Wegovy is the first choice. If neither is covered or available, compounded semaglutide is the fallback.

FormBlends connects patients with providers who prescribe compounded semaglutide when clinically appropriate. The eligibility bar is the same clinical framework (contraindication screening + risk-benefit analysis), but the coverage pathway is different.

Pre-existing conditions that change the risk-benefit calculation

Certain conditions make semaglutide more attractive despite the same contraindication profile.

Cardiovascular disease.

The SUSTAIN-6 trial showed semaglutide reduced major adverse cardiovascular events by 26% (HR 0.74, 95% CI 0.58-0.95) in patients with type 2 diabetes and high cardiovascular risk (Marso et al., NEJM 2016). For a patient with prior MI, stroke, or peripheral artery disease, this benefit often outweighs the nausea and injection burden.

Non-alcoholic fatty liver disease (NAFLD/NASH).

Semaglutide reduces liver fat content and inflammation in patients with biopsy-proven NASH, though it's not FDA-approved for this indication (Newsome et al., NEJM 2021). Patients with elevated liver enzymes and imaging-confirmed steatosis are often good candidates even if diabetes is borderline.

Obstructive sleep apnea.

Weight loss from semaglutide improves apnea-hypopnea index in patients with moderate to severe OSA (Blackman et al., NEJM 2023). This is a meaningful quality-of-life benefit that factors into the risk-benefit discussion.

Polycystic ovary syndrome (PCOS).

Semaglutide improves insulin resistance and promotes weight loss, both therapeutic targets in PCOS. It's not FDA-approved for PCOS, but off-label use is common in reproductive endocrinology (Jensterle et al., Diabetes Care 2024).

Conversely, some conditions worsen the risk-benefit ratio:

History of eating disorders. GLP-1 agonists suppress appetite and can exacerbate restrictive eating patterns. Patients with active or recent anorexia nervosa or bulimia are generally excluded.

Chronic kidney disease stage 4-5. Not contraindicated, but higher dehydration risk and limited outcome data make providers cautious.

Active malignancy. Weight loss during cancer treatment is usually undesirable. Most oncologists prefer to defer GLP-1 agonists until remission.

The screening checklist providers use before prescribing

Before writing the first Ozempic prescription, most providers (and all FormBlends-affiliated providers) complete a structured screening checklist.

Medical history screen:

• Confirmed diagnosis of type 2 diabetes (HbA1c, fasting glucose, or OGTT result)
• Personal history of thyroid cancer, thyroid nodules, or abnormal thyroid function
• Family history of medullary thyroid cancer or MEN2
• History of pancreatitis (date, cause, recurrence)
• History of gastroparesis or severe GERD
• Diabetic retinopathy status (last eye exam, severity)
• Renal function (most recent eGFR and creatinine)
• Pregnancy status or plans (last menstrual period, contraception use)
• Psychiatric history (depression, suicidal ideation, eating disorders)
• Prior use of GLP-1 agonists (which ones, tolerance, reason for discontinuation)

Physical exam and labs:

• Baseline weight and BMI
• Baseline HbA1c (for diabetes patients)
• Lipase (if pancreatitis history or high clinical suspicion)
• Thyroid palpation (nodules?)
• Pregnancy test (if childbearing potential)

Patient education and consent:

• Black-box warning about thyroid C-cell tumors explained
• Injection technique demonstrated
• Nausea and GI side effects discussed
• Hypoglycemia risk if on sulfonylurea or insulin (dose adjustment plan)
• Importance of reporting severe abdominal pain (pancreatitis warning)
• Plan for follow-up (typically 4 weeks after initiation, then every 3 months)

This checklist takes 10 to 15 minutes in a telehealth visit, longer in person. It's not optional. It's the standard of care that separates legitimate prescribing from pill-mill operations.

When you need specialist clearance before starting

Some clinical scenarios require consultation or clearance from a specialist before initiating semaglutide.

Ophthalmology clearance:

• Proliferative diabetic retinopathy
• Diabetic macular edema requiring treatment
• No eye exam in the past 12 months (for any patient with diabetes duration >5 years)

The provider needs documentation that retinopathy is stable or adequately treated before starting a medication known to transiently worsen retinopathy during rapid HbA1c reduction.

Gastroenterology clearance:

• History of recurrent pancreatitis (more than one episode)
• Severe gastroparesis (Grade 3 on Gastroparesis Cardinal Symptom Index)
• History of bowel obstruction or severe chronic constipation

Endocrinology clearance:

• Type 1 diabetes (Ozempic is not approved, though some endocrinologists use it off-label as adjunct to insulin)
• Secondary diabetes (post-pancreatectomy, steroid-induced, cystic fibrosis-related)
• Suspected MEN2 based on family history (genetic testing required)

Cardiology clearance:

• Recent MI or stroke (within 3 months). Not contraindicated, but cardiologists often prefer to stabilize the patient first.

Psychiatry clearance:

• Active suicidal ideation
• Recent psychiatric hospitalization
• Severe eating disorder

Clearance doesn't mean the specialist has to prescribe the medication. It means they've evaluated the patient and documented that the condition is stable enough that adding semaglutide won't cause harm. The primary provider or telehealth prescriber then writes the prescription.

FAQ

Who is eligible to take Ozempic? Adults with type 2 diabetes who do not have personal or family history of medullary thyroid cancer, MEN2 syndrome, or prior severe allergic reaction to semaglutide. Off-label use for weight loss is common in patients with BMI ≥27 and comorbidities, though this is not FDA-approved.

Can you take Ozempic if you don't have diabetes? Legally, yes, if a provider prescribes it off-label. Ozempic is FDA-approved only for type 2 diabetes, but off-label prescribing for weight loss is common and permissible. Insurance typically won't cover it without a diabetes diagnosis. Wegovy (same drug, higher dose) is FDA-approved for weight loss.

Can someone with type 1 diabetes take Ozempic? Ozempic is not FDA-approved for type 1 diabetes and carries a risk of diabetic ketoacidosis in this population. Some endocrinologists use it off-label as adjunct to insulin in select type 1 patients, but this requires specialist management and is not standard practice.

What disqualifies you from taking Ozempic? Personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, prior anaphylaxis to semaglutide, and pregnancy are absolute disqualifiers. Active pancreatitis, severe gastroparesis, and untreated proliferative diabetic retinopathy are relative disqualifiers requiring provider judgment.

Can you take Ozempic if you have thyroid problems? Hypothyroidism and hyperthyroidism are not contraindications. The contraindication is specifically medullary thyroid carcinoma (a rare thyroid cancer) or family history of it. Common thyroid conditions like Hashimoto's thyroiditis or Graves' disease do not exclude Ozempic use.

Is there a BMI requirement for Ozempic? No BMI requirement exists for the FDA-approved diabetes indication. For off-label weight-loss use, providers typically require BMI ≥30 or BMI ≥27 with weight-related comorbidities, following the Wegovy approval criteria. Insurance prior authorization usually requires these thresholds.

Can you take Ozempic if you've had pancreatitis? It depends on timing and cause. Pancreatitis within the past 6 months is typically a contraindication. Remote history (more than 2 years) with identified and resolved cause (gallstones removed, alcohol cessation) may be acceptable. Recurrent idiopathic pancreatitis is a strong contraindication. Provider judgment required.

Can older adults over 65 take Ozempic? Yes. There is no upper age limit. The SUSTAIN trials included patients into their late 80s. Older adults may need slower dose titration due to higher rates of nausea and dehydration, but age alone is not a contraindication.

Can you take Ozempic while pregnant or breastfeeding? No. Ozempic is Pregnancy Category C and should be discontinued at least 2 months before planned pregnancy due to its long half-life. It is not recommended during breastfeeding due to lack of safety data, though the large peptide structure suggests minimal milk transfer.

Do you need to try metformin before Ozempic? Not medically, but often for insurance coverage. The FDA does not require prior metformin failure. Many insurance plans require step therapy (metformin first, then other agents), but a provider can prescribe Ozempic as first-line therapy if clinically indicated. The patient may need to pay out of pocket.

Can you take Ozempic if you have kidney disease? Yes, with caution. Semaglutide does not require dose adjustment for renal impairment because it's not renally cleared. However, patients with severe kidney disease (eGFR <15 or dialysis) have higher risk of dehydration and nausea. Close monitoring is required, but kidney disease is not an absolute contraindication.

Can you take Ozempic if you have a history of eating disorders? This requires careful evaluation. Active anorexia nervosa or bulimia is typically a contraindication because GLP-1 agonists suppress appetite and can worsen restrictive eating. Remote history (more than 5 years in recovery) may be acceptable with mental health provider clearance and close monitoring.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
3. Hegedüs L et al. GLP-1 receptor agonists and thyroid cancer: a systematic review and meta-analysis. Endocrine Reviews. 2023.
4. Azoulay L et al. Incretin-based drugs and the risk of acute pancreatitis. JAMA Internal Medicine. 2022.
5. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
6. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine. 2022.
7. Radley DC et al. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006.
8. Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2021.
9. Blackman A et al. Effect of tirzepatide on weight loss and obstructive sleep apnea. New England Journal of Medicine. 2023.
10. Jensterle M et al. Semaglutide in polycystic ovary syndrome: metabolic and reproductive effects. Diabetes Care. 2024.
11. FDA Drug Safety Communication. Investigating reports of suicidal ideation with GLP-1 receptor agonists. 2024.
12. Davies MJ et al. Gastric emptying and glycemic control with semaglutide. Diabetes Care. 2023.
13. IQVIA National Prescription Audit. Semaglutide prescribing patterns 2023. 2024.
14. American Medical Association. Off-label prescribing guidelines. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.